Improvement of non-alcoholic fatty liver disease treatment
Aim of investigation. To estimate efficacy of combined hepatotropic drug «Hepaguard Active» for prevention of progression of non-alcoholic fatty liver disease (NAFLD) at steatosis stage.Material and methods. Overall 25 patients with verified NAFLD at steatosis stage were studied. All patients receiv...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2014-10-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/1127 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860043818205184 |
|---|---|
| author | P. I. Seliverstov V. G. Radchenko |
| author_facet | P. I. Seliverstov V. G. Radchenko |
| author_sort | P. I. Seliverstov |
| collection | DOAJ |
| description | Aim of investigation. To estimate efficacy of combined hepatotropic drug «Hepaguard Active» for prevention of progression of non-alcoholic fatty liver disease (NAFLD) at steatosis stage.Material and methods. Overall 25 patients with verified NAFLD at steatosis stage were studied. All patients received Hepaguard Active 1 capsule tid at meal time for 3 months. Before and after treatment course general examination was performed, including: inquiry and physical examination, clinical and biochemical blood tests, FibroMax tests, large intestine contents culture, bioimpedance analysis of componental body composition, ultrasound investigation of abdominal organs.Results. On a background of «Hepaguard Active» therapy improvement of symptoms was marked, condition of hepatobiliary tract has improved, lipid spectrum was normalized, excessive body weight decreased, quality of life improved.Conclusions. Hepaguard Active can be recommended to patients with NAFLD at steatosis stage for correction of revealed disorders and prevention of disease progression. |
| format | Article |
| id | doaj-art-5ba22fc738fb424881a1d840dd17e5cb |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2014-10-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-5ba22fc738fb424881a1d840dd17e5cb2025-02-10T16:14:39ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732014-10-012443944727Improvement of non-alcoholic fatty liver disease treatmentP. I. Seliverstov0V. G. Radchenko1State educational government-financed institution of higher professional education Mechnikov North-Western State Medical University, Ministry of Healthcare of the Russian FederationState educational government-financed institution of higher professional education Mechnikov North-Western State Medical University, Ministry of Healthcare of the Russian FederationAim of investigation. To estimate efficacy of combined hepatotropic drug «Hepaguard Active» for prevention of progression of non-alcoholic fatty liver disease (NAFLD) at steatosis stage.Material and methods. Overall 25 patients with verified NAFLD at steatosis stage were studied. All patients received Hepaguard Active 1 capsule tid at meal time for 3 months. Before and after treatment course general examination was performed, including: inquiry and physical examination, clinical and biochemical blood tests, FibroMax tests, large intestine contents culture, bioimpedance analysis of componental body composition, ultrasound investigation of abdominal organs.Results. On a background of «Hepaguard Active» therapy improvement of symptoms was marked, condition of hepatobiliary tract has improved, lipid spectrum was normalized, excessive body weight decreased, quality of life improved.Conclusions. Hepaguard Active can be recommended to patients with NAFLD at steatosis stage for correction of revealed disorders and prevention of disease progression.https://www.gastro-j.ru/jour/article/view/1127non-alcoholic fatty liver diseasesteatosishepaguard active |
| spellingShingle | P. I. Seliverstov V. G. Radchenko Improvement of non-alcoholic fatty liver disease treatment Российский журнал гастроэнтерологии, гепатологии, колопроктологии non-alcoholic fatty liver disease steatosis hepaguard active |
| title | Improvement of non-alcoholic fatty liver disease treatment |
| title_full | Improvement of non-alcoholic fatty liver disease treatment |
| title_fullStr | Improvement of non-alcoholic fatty liver disease treatment |
| title_full_unstemmed | Improvement of non-alcoholic fatty liver disease treatment |
| title_short | Improvement of non-alcoholic fatty liver disease treatment |
| title_sort | improvement of non alcoholic fatty liver disease treatment |
| topic | non-alcoholic fatty liver disease steatosis hepaguard active |
| url | https://www.gastro-j.ru/jour/article/view/1127 |
| work_keys_str_mv | AT piseliverstov improvementofnonalcoholicfattyliverdiseasetreatment AT vgradchenko improvementofnonalcoholicfattyliverdiseasetreatment |